Pharma channel feed – Endpoints News

Pharma channel feed

Cures Act implementation: Gottlieb says faster cancer drug approvals coming for secondary indications

8 years ago

Major deregulation? FDA withdraws several rules and regulations related to medical products

8 years ago

After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab

8 years ago

In latest deal, Melinta executes $270M pact to buy out Medicines Co’s infectious disease group

8 years ago

Regeneron and Decibel aren’t just collaborating: They want to create a whole new partnering model

8 years ago

How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash

8 years ago

Roiled by financial turmoil, Teva's CEO boots R&D chief, top execs in C-suite overhaul

8 years ago

Biogen’s answer to Alkermes’ Tecfidera threat? Buy it, but don’t spend too much

8 years ago

Merck blueprints $1.3B research hub in a post-Brexit London, with 950 staffers

8 years ago

Teva R&D chief out as new CEO picks up the ax and aims at deep cuts to rescue a faltering biopharma — report

8 years ago

Under pressure from copycats, Roche sues Pfizer over Herceptin rival

8 years ago

With billions riding on their success, GSK bags quick OK for its two-drug HIV combo Juluca

8 years ago

After unexpected tie, Amsterdam wins 'coin toss' for new EMA HQ

8 years ago

The top 10 hit parade of biopharma licensing deals for 2014-2017

8 years ago

Bayer AG taps PeptiDream in billion-dollar deal

8 years ago

FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency

8 years ago

A go-go FDA is opening up the fast lane to regenerative med approvals

8 years ago

Struggling Oncolytics Biotech signs $86.6M Asia deal with China's Adlai Nortye

8 years ago

Booming Regeneron gets the green light for a major expansion

8 years ago

FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering

8 years ago

The Pentagon's compromise: drug approvals to remain in FDA's hands

8 years ago

In blow to Shire, Roche bags an FDA OK for its blockbuster hemophilia A prospect

8 years ago

J&J goes back to Ionis for its second experimental pill for a GI autoimmune disease

8 years ago

You want to charge $1M for that gene therapy? Here’s where you’re wrong

8 years ago

First page Previous page 308 309 310311312 313 314 Next page Last page